Or it may cause gastrointestinal side effects, such as cramping or diarrhea
The search strategy used for the Europe PMC database was: TITLE_ABS:((Akkermansia muciniphila OR Akkermansia) AND (insulin resistance OR glucose metabolism OR insulin sensitivity)) Furthermore, ClinicalTrials.gov and the Cochrane Library were used to identify high-quality relevant articles and research trials with a global scope that are rigorously evaluated to fit the research question
doi: 10.1007/s10238-015-0345-6 5 SuGZhongZZhouQDuLYeZLiFet al
Funnel plots of the reductions in BMI, body weight, WC, WHR and AG of the patients indicated no publication bias (Fig
Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide What patients do after stopping a GLP-1 medication and how their weight changes afterward turns out to be more varied than controlled trials have suggested
In one of the focus groups, there was no disagreement when one participant asked, [d]oes it feel almost inevitable that those drugs are going to become part of our formulary? Our insurance provider, Cigna told us that within the next 9 to 12 months, theres really not going to be a choice, that all insurance companies are probably going to be covering GLP-1s for weight loss. Occupational health manager, large manufacturer The use of GLP-1 drugs for weight loss is still new for many employers, and many are not sure how or whether they can manage the benefit
